Hypertension: Treatment of essential hypertension in adults. Cardiovascular prevention: Reduction of cardiovascular morbidity in adults with:
• manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or
• type 2 diabetes mellitus with documented target organ damage.
Dosage & Administration
Treatment of hypertension: In case of hypertension usually 40 mg once daily for at least 4 weeks. Increased if necessary up to maximum 80 mg once daily. Blood pressure response is dose related over the range of 20 mg to 80 mg. Cardiovascular risk reduction: 40 mg twice daily or 80 mg once daily.
Use in Specific Population
Use in pregnancy: Telmisartan is US-FDA pregnancy category D drug. When pregnancy is detected or expected, Telmisartan should be discontinued as soon as possible. Use in Lactation: It is not known whether Telmisartan passes into human milk. Decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother, the importance of nursing to the infant. Hepatic Insufficiency: Caution should be taken in patients with biliary obstructive disorders or hepatic insufficiency. Geriatric patients (>65 years of age): No overall differences in effectiveness and safety were observed in these patients compared to younger patients. Pediatric patients: Safety and effectiveness in pediatric patients have not been established.
Olmevas AMAmlodipine + Olmesartan
Glycenor MEmpagliflozin & Metformin Hydrochloride